Human metapneumovirus fusion glycoprotein (hMPV F) (hMPV F)

The Human metapneumovirus (hMPV) fusion (F) glycoprotein is a critical class I viral fusion protein that mediates the entry of the virus into host respiratory epithelial cells. It is synthesized as an inactive precursor, F0, which must be proteolytically cleaved into disulfide-linked F1 and F2 subunits by host cell proteases to become fusion-competent [1, 2]. Unlike many other paramyxoviruses, the hMPV F protein can facilitate both attachment and fusion independently of the attachment (G) protein, often by binding to host cell surface heparan sulfate and RGD-binding integrins such as alpha-v-beta-1 [1, 11]. The protein undergoes a dramatic, irreversible conformational change from a metastable prefusion state to a stable postfusion state to drive the merger of the viral envelope with the host cell membrane [15, 18]. As the primary target for neutralizing antibodies, the F protein is the focus of intensive research for the development of vaccines and therapeutic monoclonal antibodies [4, 5]. While no specific antivirals or vaccines are currently FDA-approved, several candidates, including mRNA-based vaccines and potent neutralizing antibodies like DS7 and M75, are in various stages of development [17, 18, 20]. Therapeutic strategies often aim to stabilize the prefusion conformation or block the fusion peptide's insertion into the host membrane [4, 15]. Challenges in targeting this molecule include the high degree of conformational instability, strain-specific pH requirements for triggering, and the potential for viral escape through mutations in conserved antigenic sites [13, 16].

Other names

hMPV F proteinFusion proteinF0 glycoproteinF1/F2 heterodimerHuman metapneumovirus fusion proteinClass I viral fusion protein

Inhibition of viral membrane fusion, neutralization of viral infectivity, blockade of viral attachment to host cells, and stabilization of the prefusion conformation to prevent structural rearrangement.